Nerviano gets FDA nod for Ph I antitumor trial

Italy's Nerviano Medical Sciences has secured US Food and Drug Administration approval to conduct clinical trials of a novel  antitumoral agent.

The drug blocks Cdc7, a protein that is responsible for the uncontrolled  proliferation of cancer cells. The preclinical data, recently published  on the journal Nature Chemical Biology, demonstrate that inhibition of  Cdc7 induces tumor cell death and blocks the growth of various types of  cancer in experimental animal models.